A managed access program of Habeo cell therapy (ECCS-50)
Latest Information Update: 20 Jan 2020
Price :
$35 *
At a glance
- Drugs ECCS 50 (Primary)
- Indications Scleroderma
- Focus Expanded access; Therapeutic Use
- 20 Jun 2017 New trial record
Latest Information Update: 20 Jan 2020